Viome and Helomics Team Up to Study Possible Links Between Gut Microbiome and Ovarian Cancer

Viome and Helomics Team Up to Study Possible Links Between Gut Microbiome and Ovarian Cancer
With the aim of advancing personalized therapy, a pilot study will investigate a possible correlation between gut microbiome and ovarian cancer. The investigation is the initial development of a new partnership between Viome, whose proprietary gut microbiome test is used to personalize diet and nutrition recommendations, and Helomics, which seeks to improve standards of patient care through more and improved tailored treatments and diagnostic tools. Results will be announced at the pilot’s conclusion. The length of the study is unclear. “We are excited to kick off this novel study to help the millions of women suffering from ovarian cancer,” Naveen Jain, Viome CEO and founder, said in a press release. “We believe the outcome of our work will be revolutionary and will offer powerful insights and effective treatments for patients.” The study will combine Viome’s microbiome analysis and artificial intelligence (AI) platforms with Helomics’ proprietary drug response and genomic profiling of patients' tumors, and its AI-fueled bioinformatics platform (D-CHIP). The teams will look for any difference in gut microbiome between those with and without ovarian cancer. “Helomics pioneered using knowledge gained from drug response and genomic profiling of the patient’s living tumor to help individualize ovarian cancer therapy,” said Gerald Vardzel, president and CEO
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *